1. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus Flavivirus. J Virol. 1998; 72:73–83.
2. Halstead SB. Dengue. Lancet. 2007; 370:1644–1652.
3. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest. 2004; 113:946–951.
4. Fields BN, Knipe DM, Howley PM. Fields' virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins;2007.
5. Crill WD, Chang GJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004; 78:13975–13986.
6. Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology. 1998; 246:317–328.
7. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004; 427:313–319.
8. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol. 2001; 75:7769–7773.
9. Chavez JH, Silva JR, Amarilla AA, Moraes Figueiredo LT. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals. 2010; 38:613–618.
10. Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Ther Pat. 2010; 20:819–835.
11. Puigbo P, Guzman E, Romeu A, Garcia-Vallve S. OPTIMIZER: a web server for optimizing the codon usage of DNA sequences. Nucleic Acids Res. 2007; 35:W126–W131.
12. Vincze T, Posfai J, Roberts RJ. NEBcutter: a program to cleave DNA with restriction enzymes. Nucleic Acids Res. 2003; 31:3688–3691.
13. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003; 31:3406–3415.
14. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol. 1996; 266:540–553.
15. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng. 2001; 14:529–532.
16. Amani J, Mousavi SL, Rafati S, Salmanian AH. In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications. Theor Biol Med Model. 2009; 6:28.
17. Koraka P, Martina BE, Osterhaus AD. Bioinformatics in new generation flavivirus vaccines. J Biomed Biotechnol. 2010; 2010:864029.
18. Holbrook MR, Shope RE, Barrett AD. Use of recombinant E protein domain III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis serocomplex flaviviruses from mosquito-borne flaviviruses. J Clin Microbiol. 2004; 42:4101–4110.
19. Fahimi H, Allahyari H, Hassan ZM, Sadeghizadeh M. Dengue virus type-3 envelope protein domain III; expression and immunogenicity. Iran J Basic Med Sci. 2014; 17:836–843.
20. Burgess-Brown NA, Sharma S, Sobott F, Loenarz C, Oppermann U, Gileadi O. Codon optimization can improve expression of human genes in Escherichia coli: a multi-gene study. Protein Expr Purif. 2008; 59:94–102.
21. Tong JC, Tan TW, Ranganathan S. Methods and protocols for prediction of immunogenic epitopes. Brief Bioinform. 2007; 8:96–108.
22. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990; 276:172–174.